The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Airway inflammation is partly driven by Th17 and Th17-polarizing cytokines that is steroid-resistant. Statins could suppress IL-17 cytokines in other diseases such as atherosclerosis and multiple sclerosis in mouse model. The investigators hypothesize that statins might provide anti-inflammatory benefit of suppressing IL-17 cytokines in COPD patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Treatments: Simvastatin

Criteria

Inclusion Criteria:

• Stable COPD without an exacerbation within 3 months prior to study entry

• mild, moderate and severe COPD with or without treatments, regardless of COPD medications

Exclusion Criteria:

• Concomitant other chronic lung diseases including with TB and malignancy

• HIV

• Being on immunosuppressive drugs and systemic corticosteroids

• Dyslipidemic patients with recent cardiovascular or cerebrovascular disease within 6 month prior to study entry

• Cognitive impairment

• Currently on macrolides, azole anti-fungal agents, amiodarone and amlodipine